Invention Grant
- Patent Title: Humanized anti CXCR4 antibodies for the treatment of cancer
- Patent Title (中): 人源化抗CXCR4抗体治疗癌症
-
Application No.: US13637198Application Date: 2011-03-30
-
Publication No.: US09249223B2Publication Date: 2016-02-02
- Inventor: Christine Klinguer-Hamour , Alexandra Jouhanneaud , Véronique Grenier-Caussanel
- Applicant: Christine Klinguer-Hamour , Alexandra Jouhanneaud , Véronique Grenier-Caussanel
- Applicant Address: FR Boulogne-Billancourt
- Assignee: Pierre Fabre Medicament
- Current Assignee: Pierre Fabre Medicament
- Current Assignee Address: FR Boulogne-Billancourt
- Agency: Finnegan, Henderson, Farabow, Garrett and Dunner, L.L.C.
- Priority: EP10290167 20100330
- International Application: PCT/EP2011/054945 WO 20110330
- International Announcement: WO2011/121040 WO 20111006
- Main IPC: C07K16/00
- IPC: C07K16/00 ; A61K39/395 ; C07K16/28 ; A61K39/00
Abstract:
The present invention relates to a novel isolated humanized antibody, or the derived compounds or functional fragments of same, capable of binding to CXCR4 but also of inducing conformational changed of the CXCR4 homodimers and/or heterodimers. More particularly, the present invention relates to hz515H7 antibodies, specific to the CXCR4 protein, as well as their use for the treatment of cancer. Pharmaceutical compositions composed of such antibodies and a process for the selection of such antibodies are also covered.
Public/Granted literature
- US20130031647A1 HUMANIZED ANTI CXCR4 ANTIBODIES FOR THE TREATMENT OF CANCER Public/Granted day:2013-01-31
Information query
